Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 16, 2011

Standard of Care, Overseas Opportunities Top Strategies Firms Use to Overcome MDX Reimbursement Issues

  • Exactly half of respondents to a GEN poll say their companies are working to gain provider acceptance and reimbursement for personalized medicine by pursuing standard-of-care status for their molecular diagnostics. Another third (33.3%) are concentrating their efforts on developing diagnostics for markets outside the U.S., while 16.7% said they are forming partnerships with the pharmaceutical industry. Steven Burrill, CEO of Burrill & Company, has likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.”

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.